STAT2d
Experts fear disruptions at FDA as Trump offers buyouts and layoff reports swirl
The Trump administration’s overarching message to the legions of people powering the federal government is simple: Leave.
Biodexa stock soars 76% on FDA Fast Track status for eRapa
Biodexa (NASDAQ:BDRX) stock soared 76% in morning trading after the company announced it has received FDA Fast Track designation for its drug eRapa for the treatment of familial adenomatous polyposis, ...
The FDA just approved a new painkiller. Is it too good to be true?
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
STAT6h
The FDA’s misguided thinking on antibiotics
You probably think “antibiotic resistance” means that a bacterial infection can’t be cured by any antibiotics. But the FDA ...
Healio2h
FDA grants brensocatib priority review for bronchiectasis
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...
FDA recalls more than 2 million cases of doughnuts
The FDA recalled 60 doughnut products, totaling more than 2 million cases, for potential listeria contamination. The ...
pharmaphorum3h
FDA clears new antibiotic for superbug infections
AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...
Health groups sound alarm on missing CDC, FDA data
Prominent health care organizations urge the Trump administration to restore important data sets on the Centers for Disease ...
FiercePharma3h
AbbVie scores FDA nod for Pfizer-partnered antibiotic Emblaveo
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
Oncocyte secures $29.1 million to advance FDA assay
IRVINE, Calif. - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, has announced a funding round led by ...